Skip to main
TTRX

TTRX Stock Forecast & Price Target

TTRX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Turn Therapeutics Inc, a clinical-stage biotechnology company specializing in dermatology and wound care, benefits from its proprietary PermaFusion technology, which enhances drug performance and aligns with market expectations for chronic inflammatory dermatologic conditions. The company's lead drug candidate, GX-03/Hexagen, targets the significant U.S. eczema market of approximately 16.5 million patients, positioning Turn for substantial revenue opportunities as it pursues commercialization pathways. Additionally, the successful advancement of its assets is bolstered by favorable reimbursement dynamics and the potential for strategic partnerships with larger players in the dermatology sector.

Bears say

Turn Therapeutics Inc faces a challenging financial outlook due to its dependency on milestone-based funding structures, which limit immediate capital availability and create potential future overhangs that could suppress stock performance. The company's focus on under-treated conditions, such as onychomycosis, reveals a market characterized by low treatment penetration, high recurrence rates, and modest cure rates, leading to ongoing patient challenges and limited revenue generation opportunities. Additionally, the inherent volatility and investment risks associated with small-cap biotechnology firms further contribute to a cautious perspective on Turn Therapeutics's stock.

TTRX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Turn Therapeutics Inc (TTRX) Forecast

Analysts have given TTRX a Strong Buy based on their latest research and market trends.

According to 1 analysts, TTRX has a Strong Buy consensus rating as of Apr 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Turn Therapeutics Inc (TTRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.